ArticleNPJ precision oncology2025
Comprehensive analysis of PIK3CA mutations in advanced colorectal cancer using circulating tumor DNA profiling.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Analysis of PIK3CA mutation prevalence variation among colorectal cancer populations: a comprehensive review.Molecular biology reports · 2025Pooled it
- Recurrent PIK3CA-E545K mutation promotes cervical cancer growth and invasion via AKT/mTOR signaling.Molecular genetics and genomics : MGG · 2026Article
- OncogenicJournal for immunotherapy of cancer · 2026Article
- Chemical programming of kinase inhibitors in a modular chemputer-based system.Communications biology · 2026Article
- Analytical and clinical validation of a novel CE-IVD kit forThe journal of liquid biopsy · 2026Article
- From PIK3CA Mutations to Rational PI3K Inhibition for the Treatment of Colorectal Cancer.Molecular diagnosis & therapy · 2026Review
- Analysis of the Occurrence ofChildren (Basel, Switzerland) · 2025Article
- Chronic Liver Disease Associated Cholangiocarcinoma: Genomic Insights and Precision Therapeutic Strategies.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in PIK3CA are prevalent in advanced colorectal cancer (CRC) and are associated with advanced-stage disease and poor prognosis. However, the prognostic value of these mutations remains unclear. To better understand their role in CRC progression, we evaluated the genomic landscape of PIK3CA mutations (PIK3CAm) in advanced CRC using plasma-based ctDNA from ~17,000 samples (Guardant360 database). Mutation co-occurrence, MSI-H status, TMB scores, and exon-specific mutation frequencies were analyzed. Our study shows that the frequency of PIK3CAm (19.2%) and distribution of exons 9 and 20 are similar to those found previously in the literature. Our results demonstrate PIK3CAm having a low frequency of MSI-H co-occurrence, higher TMB scores, and increased co-occurring alterations in APC, BRAF, EGFR, ERBB2 and KRAS, which may suggest higher genomic instability. Our findings underscore the clinical significance of PIK3CAm in CRC and supports the development of tailored therapeutic strategies targeting this mutation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.